Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Aug:99:27-30.
doi: 10.1016/j.earlhumdev.2016.05.010. Epub 2016 Jul 4.

Safety of histamine-2 receptor blockers in hospitalized VLBW infants

Affiliations
Multicenter Study

Safety of histamine-2 receptor blockers in hospitalized VLBW infants

Andrew Romaine et al. Early Hum Dev. 2016 Aug.

Abstract

Background: Histamine-2 receptor (H2) blockers are often used in very low birth weight infants despite lack of population specific efficacy and safety data.

Aims: We sought to describe safety and temporal trends in histamine-2 receptor (H2) blocker use in hospitalized very low birth weight (VLBW) infants.

Study design: We conducted a retrospective cohort study using a clinical database populated by an electronic health record shared by 348 neonatal intensive care units in the United States.

Subjects: We included all VLBW infants without major congenital anomalies.

Outcome measures: We used multivariable logistic regression with generalizing estimating equations to evaluate the association between days of H2 blocker exposure and risk of: 1) death or necrotizing enterocolitis (NEC); 2) death or sepsis; and 3) death, NEC, or sepsis.

Results: Of 127,707 infants, 20,288 (16%) were exposed to H2 blockers for a total of 6,422,352days. Median gestational age for infants exposed to H2 blockers was 27weeks (25th 75th percentile 26, 29). H2 blocker use decreased from 18% of infants in 1997 to 8% in 2012 (p<0.001). On multivariable analysis, infants were at increased risk of the combined outcome of death, NEC, or sepsis on days exposed to H2 blockers (odds ratio=1.14) (95% confidence interval 1.08, 1.19).

Conclusions: H2 blocker use is associated with increased risk of the combined outcome of death, NEC, or sepsis in hospitalized VLBW infants.

Keywords: H2 blockers; Histamine-2 receptor antagonists; Infants; Necrotizing enterocolitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Temporal trend in H2 blocker use in very low birth weight infants

Similar articles

Cited by

References

    1. van der Pol R, Langendam M, Benninga M, van Wijk M, Tabbers M. Efficacy and safety of histamine-2 receptor antagonists. JAMA Pediatr. 2014 Oct;168(10):947–54. - PubMed
    1. Malcolm WF, Cotten CM. Metoclopramide, H2 blockers, and proton pump inhibitors: pharmacotherapy for gastroesophageal reflux in neonates. Clin Perinatol. 2012 Mar;39(1):99–109. - PubMed
    1. Orenstein SR, Blumer JL, Faessel HM, McGuire JA, Fung K, Li BU, et al. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2002 May;16(5):899–907. - PubMed
    1. Cucchiara S, Staiano A, Romaniello G, Capobianco S, Auricchio S. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child. 1984 Sep;59(9):842–7. - PMC - PubMed
    1. Oderda G, Dell'Olio D, Forni M, Farina L, Tavassoli K, Ansaldi N. Treatment of childhood peptic oesophagitis with famotidine or alginate-antacid. Ital J Gastroenterol. 1990 Dec;22(6):346–9. - PubMed

Publication types

Substances

LinkOut - more resources